Osamu Nureki
Fondateur chez MODALIS THERAPEUTICS CORPORATION
Fortune : 1 M $ au 30/04/2024
Profil
Osamu Nureki is the founder of Modalis Therapeutics Corp., which was founded in 2016.
He holds the title of Outside Director at the company.
He is also currently working as an Outside Director at Curreio, Inc. since 2019.
Additionally, he has been a Professor at the University of Tokyo since 2008.
Dr. Nureki completed his undergraduate and graduate degrees at the University of Tokyo.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/12/2023 | 2 266 100 ( 6,16% ) | 1 M $ | 30/04/2024 |
Postes actifs de Osamu Nureki
| Sociétés | Poste | Début |
|---|---|---|
| MODALIS THERAPEUTICS CORPORATION | Fondateur | 01/01/2016 |
Curreio, Inc.
 Curreio, Inc. Pharmaceuticals: MajorHealth Technology Curreio, Inc. is a drug discovery startup company founded in August 2019 and based in Tokyo, Japan. The Japanese company specializes in cryo-EM structural analysis technology and has unique technologies and know-how in protein production and purification, grid preparation, and 3D structural analysis. Curreio is currently developing internal/collaborative drug discovery projects and drug discovery support services for pharmaceutical companies using their cryo-EM technologies. The company's goal is to expand the possibilities of drug discovery for challenging proteins and protein-supramolecular complexes through structural analysis. The CEO is Motoki Nakai. | Directeur/Membre du Conseil | 01/11/2019 |
| University of Tokyo | Corporate Officer/Principal | 01/04/2008 |
Formation de Osamu Nureki
| University of Tokyo | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MODALIS THERAPEUTICS CORPORATION | Health Technology |
| Entreprise privées | 1 |
|---|---|
Curreio, Inc.
Curreio, Inc. Pharmaceuticals: MajorHealth Technology Curreio, Inc. is a drug discovery startup company founded in August 2019 and based in Tokyo, Japan. The Japanese company specializes in cryo-EM structural analysis technology and has unique technologies and know-how in protein production and purification, grid preparation, and 3D structural analysis. Curreio is currently developing internal/collaborative drug discovery projects and drug discovery support services for pharmaceutical companies using their cryo-EM technologies. The company's goal is to expand the possibilities of drug discovery for challenging proteins and protein-supramolecular complexes through structural analysis. The CEO is Motoki Nakai. | Health Technology |